Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lyell Immunopharma filings document the regulatory record of a Nasdaq-listed clinical biotechnology company developing next-generation CAR T-cell therapies. Its 8-K reports furnish operating results and business updates for ronde-cel in large B-cell lymphoma and LYL273 in metastatic colorectal cancer and other GCC-expressing cancers, along with cash, financing and clinical-program disclosures.
The company’s filings also cover material agreements, including licensing rights for LYL273, and governance matters such as annual-meeting proposals, director elections, auditor ratification, executive compensation votes, officer appointments and compensatory arrangements. Securities disclosures identify Lyell’s common stock listed on the Nasdaq Global Select Market.
Stephen J. Hill, Chief Operating Officer and director of Lyell Immunopharma (LYEL), reported two equity transactions: 8,000 shares of common stock were issued on 08/20/2025 upon vesting of performance-based restricted stock units (4,000 shares vested immediately; 4,000 remain subject to service-through vesting on 08/20/2026). The reporting person then sold 1,004 shares on 08/21/2025 to cover tax withholding at a weighted-average price of $10.544 (sale prices ranged $10.49–$10.64). Share counts reported: 16,849 shares beneficially owned after issuance and 15,845 shares after the tax-withholding sale.
Lyell Immunopharma insider trades by CFO Charles W. Newton: On 08/20/2025 Mr. Newton received 8,000 shares of Common Stock from performance-based restricted stock units that vested after certification by the compensation committee; 4,000 of those shares are immediately issued and 4,000 remain contingent for issuance on 08/20/2026 subject to continued service. Following the 08/20 issuance his beneficial ownership totaled 16,759 shares (direct).
On 08/21/2025 he sold 1,453 shares at a weighted average price of $10.544 per share to cover tax withholding. He also beneficially owns 10,000 shares indirectly through The Charles & Lisa Newton Living Trust, where he is co-trustee and co-grantor.
Lyell Immunopharma insider activity by Gary K. Lee: The company's Chief Scientific Officer received 8,000 shares on 08/20/2025 from performance-based restricted stock units, 4,000 of which vested upon certification of performance and 4,000 remain contingent on continued service through 08/20/2026. Following that issuance the reporting person beneficially owned 16,957 shares. On 08/21/2025 the reporting person sold 1,453 shares to satisfy tax withholding from the vested units at a weighted average price of $10.544 per share (sales ranged $10.49–$10.64). After the sale the beneficial ownership reported was 15,504 shares. The Form 4 was signed by an attorney-in-fact on 08/22/2025.
Lyell Immunopharma, Inc. Schedule 13G reports that Explore Investments LLC and Jeffrey P. Bezos each may be deemed to beneficially own 1,040,964 shares of Lyell common stock, representing 5.4% of the outstanding class as of the Event Date. Explore is the direct holder and Mr. Bezos is the sole member of Explore. Of the shares reported, 938,438 were acquired in the initial closing of a private placement on the Event Date. The filing notes the calculation basis of 14,808,006 total shares outstanding and disclaims beneficial ownership beyond the shares reported.
Lyell Immunopharma President and CEO Seely Lynn reported automatic sales of vested restricted stock units to satisfy tax withholding. The Form 4 shows 391 shares sold on 08/11/2025 at a weighted average price of $10.526 (range $10.045–$11.00) and 406 shares sold on 08/12/2025 at a weighted average price of $10.338 (range $10.120–$10.415).
All share amounts reflect a 1-for-20 reverse stock split effected on 05/30/2025. Following the reported transactions, the filing lists direct beneficial ownership of 35,234 shares after the first sale and 34,828 shares after the second; the sales are described as automatic to cover tax withholding on vested RSUs.
Stephen J. Hill, Chief Operating Officer and Director of Lyell Immunopharma (LYEL), reported two small disposition transactions tied to tax withholding for vested restricted stock units. On 08/11/2025 he sold 91 shares at a weighted average price of $10.526 (sale prices ranged $10.045 to $11.00), reducing his beneficial ownership to 8,943 shares. On 08/12/2025 he sold 94 shares at a weighted average price of $10.338 (sale prices ranged $10.120 to $10.415), reducing his beneficial ownership to 8,849 shares.
The Form 4 notes the shares sold were automatically disposed to satisfy tax withholding from vested RSUs, that Hill acquired 390 shares on 05/18/2025 under the company ESPP, and that LYEL effected a 1-for-20 reverse stock split on 05/30/2025; all share figures reflect that split. The Form 4 was signed by an attorney-in-fact on 08/13/2025.
Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma (LYEL), reported two routine sales of common stock on 08/11/2025 and 08/12/2025 to satisfy tax withholding obligations from vested restricted stock units. On 08/11/2025 he sold 131 shares at a weighted average price of $10.526 (range $10.045–$11.00), leaving 9,093 shares beneficially owned. On 08/12/2025 he sold 136 shares at a weighted average price of $10.338 (range $10.120–$10.415), leaving 8,957 shares beneficially owned. The Form 4 notes a 1-for-20 reverse stock split effective May 30, 2025 and inclusion of 390 ESPP shares acquired May 18, 2025. The filing was signed by an attorney-in-fact on 08/13/2025.
Newton Charles W., Chief Financial Officer of Lyell Immunopharma, Inc., reported routine share sales to satisfy tax withholding on vested restricted stock units. He sold 131 shares on 08/11/2025 at a weighted average price of $10.526 (sale prices ranged $10.045–$11.00) and 136 shares on 08/12/2025 at a weighted average price of $10.338 (sale prices ranged $10.120–$10.415), for a total of 267 shares sold.
Following those transactions the filing shows beneficial ownership figures of 8,895 shares (after the 08/11 sale) and 8,759 shares (after the 08/12 sale). The report also discloses an indirect holding of 10,000 shares held by The Charles & Lisa Newton Living Trust, of which the reporting person is co-trustee and co-grantor. The filing notes 390 shares were acquired under the company ESPP on 05/18/2025 and that all share amounts reflect a 1-for-20 reverse stock split effected 05/30/2025.
Lyell Immunopharma, Inc. is a cell therapy company advancing next-generation autologous CAR T-cell product candidates for hematologic malignancies and solid tumors. On July 25, 2025, Lyell sold and issued 3,753,752 shares of common stock in a private placement at $13.32 per share pursuant to a July 24, 2025 Purchase Agreement. The Purchase Agreement provides for the potential sale of up to $50.0 million of additional common stock to the same purchasers.
This Form S-3 registers the resale of up to 3,753,752 shares issued in that private placement so the selling stockholders may sell their shares from time to time. Lyell will not receive proceeds from resales under this prospectus and has agreed to keep the registration effective until the earlier of July 25, 2028 or the date the shares are no longer registrable. The company’s common stock trades on Nasdaq Global Select Market under the symbol LYEL; the last reported sale price on August 11, 2025 was $10.58 per share. Outstanding shares used for certain calculations were 19,211,202 as of August 7, 2025.
Lyell Immunopharma reported continued clinical progress on its lead dual-targeting CD19/CD20 CAR T candidate LYL314 and detailed mid-year financials. Total assets were $385.5 million, down from $490.9 million, driven by declines in cash and marketable securities. Cash and cash equivalents stood at $98.8 million with current marketable securities of $178.0 million, and management believes available funds are sufficient to support operations at least 12 months from the issuance of these statements.
Operating results reflect ongoing development spending: six-month R&D expense was $78.3 million and net loss was $94.9 million versus $106.5 million a year earlier, while net cash used in operating activities was $89.2 million. Clinically, Lyell advanced LYL314 into the pivotal PiNACLE trial and presented Phase 1/2 data showing an 88% overall response rate and 72% complete response rate in the 3L+ cohort with median follow-up of nine months. Subsequent events include issuance of 625,000 shares to satisfy a contingent consideration milestone and a July 2025 $50.0 million gross private placement.